Antimicrobial resistance in Neisseria gonorrhoeae compromises gonorrhoea treatment worldwide. Novel and optimized treatments and/or treatment strategies that effectively eradicate the infection with low selection of resistance are imperative. A new prospective clinical study provides further evidence that resistance-guided treatment of gonorrhoea with single-dose oral ciprofloxacin is efficacious in relevant settings and can reduce the selection pressure for resistance.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. WHO https://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/ (2012).
Unemo, M. et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sex. Health 16, 412–425 (2019).
Unemo, M. et al. Gonorrhoea. Nat. Rev. Dis. Primers. 5, 79 (2019).
Seña, A. C. et al. Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. Lancet Infect. Dis. 20, e181–e191 (2020).
Ferreyra, C. et al. Developing target product profiles for Neisseria gonorrhoeae diagnostics in the context of antimicrobial resistance: an expert consensus. PLoS ONE 15, e0237424 (2020).
Donà, V., Low, N., Golparian, D. & Unemo, M. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae. Expert Rev. Mol. Diagn. 17, 845–859 (2017).
Klausner, J. D. et al. Resistance-guided treatment of gonorrhea: a prospective clinical study. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa596 (2020).
Allan-Blitz, L.-T., Wang, X. & Klausner, J. D. Wild-type gyrase A genotype of Neisseria gonorrhoeae predicts in vitro susceptibility to ciprofloxacin: a systematic review of the literature and meta-analysis. Sex. Transm. Dis. 44, 261–265 (2017).
Unemo, M. et al. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int. J. STD AIDS (in the press).
Hadad, R. et al. Evaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in Neisseria gonorrhoeae. J. Antimicrob. Chemother. (in the press).
Acknowledgements
Work at the WHO Collaborating Centre for Gonorrhoea and other STIs is supported by grants to M.U. from the WHO, Global Antibiotic Research and Development Partnership (GARDP), Research Committee of Örebro County and the Örebro University Hospital Foundation, Örebro, Sweden.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Unemo, M. Optimizations to keep gonorrhoea treatable and reduce antimicrobial resistance selection. Nat Rev Urol 17, 609–610 (2020). https://doi.org/10.1038/s41585-020-00378-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-020-00378-5
